Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You'd have to be---Shorting at this price usually requires a "specialty" broker---and---you'd probably have to post a bond because of the riskiness below a certain s/p---which is $5 with many brokers.
Sorry for you. Now you know. TTNP is "Neverland"
TTNP news from 3-28-19:
Comprehensive Probuphine® Patient Support Services
PR Newswire PR NewswireMarch 28, 2019
SOUTH SAN FRANCISCO, Calif., March 28, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Probuphine (buprenorphine) implant, Titan's unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients.
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
More
"We believe AppianRx's comprehensive patient support services utilizing its patent pending technology platform, Cassia, will help optimize patient care by facilitating more efficient interactions among physicians, payors and specialty pharmacies," said Titan's Chief Commercial Officer, Dane Hallberg. "We expect the Cassia platform to lead to significant improvements in the automation and streamlining of the product supply chain process by managing elements such as product ordering and payor pre-approval. We look forward to working with AppianRx and plan to have the system fully operational early in the second quarter of 2019."
"We are excited that Titan has chosen AppianRx as the patient services 'hub' for Probuphine," commented Amit Jain, CEO of AppianRx. "As the Probuphine customer support center, AppianRx will manage benefits verification; prior authorization and appeals; and copay and patient assistance programs to better provide patients with access to the treatment they need. AppianRx's ability to leverage advanced automation and AI technologies allows our support staff to stay focused on what is most important - the care of the patient."
About Probuphine
Probuphine is the only subdermal implant designed to deliver buprenorphine continuously for six months following insertion.
Probuphine was developed using ProNeura™, the continuous drug delivery system developed by Titan that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and a drug substance. The resulting construct is a solid matrix that is placed subdermally, normally in the upper arm in an outpatient office procedure and removed in a similar manner at the end of the treatment period. The U.S. Food and Drug Administration (FDA) approved Probuphine in May 2016, and it is the first and only buprenorphine implant available for the maintenance treatment of opioid addiction in eligible patients.
Indication
PROBUPHINE is an implant that contains the medicine buprenorphine. PROBUPHINE is used to treat certain adults who are addicted to (dependent on) opioid drugs (either prescription or illegal). PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses (doses no more than 8 mg per day) of a transmucosal buprenorphine-containing product.
PROBUPHINE is part of a complete treatment program that also includes counseling and behavioral therapy.
---------------------------------------------------------------------------------------------------------------------
https://ih.advfn.com/stock-market/NASDAQ/titan-pharmaceuticals-inc-TTNP/stock-news/79570286/titan-pharmaceuticals-partners-with-appianrx-to-pr
You've been on Ihub since 2013---soooo----Your "rationale" is most likely legitimate-----soooo----Could you please tell us "Why" ?????
Last wenzday we wuz up 21 cents 4 the day---How cum we don't got no more days like dat since den ??????---Tell me Y ????
Dr. Reddy's relaunches Suboxone generic after court victories:
Update: Feb. 22, 2019: Mylan announced the U.S. launch of its generic version of Indivior's Suboxone, joining Dr. Reddy's on the market.
Dive Brief:
Dr. Reddy's Laboratories is reintroducing its generic version of Suboxone sublingual film in the U.S. after a series of court victories over Indivior, the maker of the opioid dependence treatment.
The U.S. Court of Appeals for the Federal Circuit in November found Indivior wasn't likely to succeed on a claim of patent infringement and ruled that a lower court's preliminary injunction stopping sales of the generic version should be lifted. Indivior then tried to block the appeals court ruling, ultimately taking the issue to the Supreme Court.
Supreme Court Chief Justice John Roberts on Feb. 19 denied Indivior's motion to stay the appeals court mandate, in effect clearing the way to market for Dr. Reddy's as the litigation continues.
----------------------------------------------------------------------------------------------------------------
Dive Insight:
The stakes are high for Indivior. The company had sales of just over $1 billion last year, most of which came from Suboxone (buprenorphine and naloxone).
When Dr. Reddy's briefly put its generic on the market in June before the court issued a preliminary injunction, Indivior's market share fell to a low of 50%, after averaging 58% the year before. The company blamed competition from Dr. Reddy's version for the dip.
Indivior subsequently gained a preliminary injunction from a U.S. district court, preventing sales of the generic and allowing its market share to largely recover by year's end. Now, the generic threat has returned and looks likely to persist.
Indivior is attempting to mitigate the damage by introducing an authorized generic version of its own, which is being sold by Sandoz.
The authorized generic will carry a wholesale acquisition cost 14% below that of Indivior's branded version, a spokesperson for Sandoz confirmed in an emailed statement.
Indivior said in a Feb. 20 statement that it's possible other generic companies will jump into the market as well. The company also has another opioid-addiction treatment known as Sublocade (buprenorphine extended-release), which posted $12 million in sales last year.
Dr. Reddy's will be selling its version of Suboxone "at risk," meaning the company could be subject to damages if it ultimately loses the patent fight. Mylan, which along with Dr. Reddy's won FDA approval for its generic version of the medicine in June, announced the U.S. launch of its copy on Feb. 22.
Dr. Reddy's has already begun shipping its generic version, according to a Feb. 20 statement. The company noted that the original injunction didn't stop it from manufacturing the medicine.
The drug helps treat both pain and addiction to opioids. Patients put the film under the tongue or inside the chee
-------------------------------------------------------------------------------------------------------------
https://www.biopharmadive.com/news/dr-reddys-relaunches-suboxone-generic-after-court-victories/548907/
Probably "dreamers"---dreaming about what you & they "thought" & what might have been & should have been----& if there is some "insider news" due but not posted on the 19th---that accounts for the up .21 cents today---insider news is always leaked out & is incestuous.---but---this same situation has occurred numerous times in the past, & has always been a "fluke"--Wouldn't it be nice, if this was the beginning of the "real deal ?.
I apologize to you for that---I shouldn't do that to TTNP newbies-----But----TTNP mngt Marc & Sunil have screwed us soooooo bad, that I & others will never recover our losses here due to their subterfuge---I feel like I've given one of them at least 1/2 the price of a nice new car.----consequently, I probably have a "mean" streak in me. Nothing ever seems to have gone right at TTNP Re: positive cash flow.
Why was it at $6---supposed to got $12----went down to 20 cents----Did 5-1 Reverse Split & is now where it is ??????? Here you are "wondering"---when their past performance tells it all.. I was a "fool" for getting into this at $6----What do you suppose the traders "are"-----that are getting into it now ?????. This is a $1/2 million$ salary per annum blow job for the "owners"???????---I wouldn't call them "owners"---There's plenty "better" words. U get the pic now ???????
Gazillion Oxycontin lawsuits, & quasi-legal over- prescribing---Have brought about a new problem---with possible "delusions"---LOLOL" without dilution---LOLOL. Check out this bull$hit:
------------------------------------------------------------------------------------------------------------------------
BETTER THAN OXYCONTIN? THE BEST NATURAL PAINKILLER THAT GROWS IN YOUR BACKYARD WITH ZERO SIDE EFFECTSWonder Drug Has ZERO SIDE EFFECTS: Retired doctor who experienced nonstop agony discovers a novel treatment for chronic pain, inflammation, anxiety, insomnia, IBD, IBS, arthritis, diabetes, hypertension, allergies and asthma! Sounds too good to be true?
Jamie Richardson from Melbourne, Australia just netted one of the biggest deals in Shark Tank history.
All 5 investors on ABC's Shark Tank teamed up to buy 30% of Richardson's breakthrough "miracle pain relief" formula for a staggering $2.9 million dollars.
Here's what it's all about...
In 2016, Dr. Jamie Richardson sold over 1.9 million bottles of his family's secret pain relief discovery called Sera Relief CBD Oil, after a bill passed in Parliament legalized the sale of CBD products in Australia.
Sera Relief CBD Oil is made from Cannabidiol (CBD), the non-psychoactive ingredient in cannabis. It is the ingredient in cannabis that relieves pain, fights inflammation, regulates blood sugar, promotes restful sleep, reduces anxiety, along with a slew of other miraculous benefits.
Sera Relief CBD Oil has been called "Nature's Oxycontin" because it quickly relieves even the most agonizing pain and reduces inflammation allowing the body to finally heal.Millions of Australians are already using Sera Relief CBD Oil on a day to day basis. Many say it works like magic. Some say it works better than prescription painkillers like Vicodin and Oxycontin.
Melody---I've always admired your wisdom---Bleak situation as long as Marc & Sunil hold the reins. How to turn this condition around?????????
From 10 years ago:---- The outcome of the patent issue could have been all that a potential buyer was waiting on because now that potential buyer knows that they will have Probuphine patent protection for the opiate indication until 2023. Time is running out on the patents
------------------------------------------------------------------------------------------------------------------------
https://seekingalpha.com/article/176196-titan-pharmaceutical-more-likely-buyout-target-as-patent-protection-is-approved
I'd love to see some pumpers come aboard that were "like" stock broker financial advisers, etc ,etc, even if were surrealism, and "lend" some "credence" to TTNP----But---- All we get is Ihub's transient jive-a$$ $hitrappers that coodint evin spel korreckly. We need to get "noticed" by the right crowd. It's possible that Sunil & Marc are working on this-----But-----????????????
U still don't get it-----Spoze to double,-------triple-----quadruple----etc-----etc----like the first Walmart store----NOT like the huge corp Walmart is today ----R U OK ???? ---------Kinda smells more like keepin' the doors open for more $500,000 salaries.
Titan Pharmaceuticals Selects Life Sciences Business Intelligence CRM Innovator, TikaMobile, to Empower its Sales and MSL Teams
------------------------------------------------------------------------------------------------------------------------
February 11, 2019 14:00 ET | Source: TikaMobile, Inc.
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- TikaMobile, a premier cloud-based business intelligence CRM provider for the life sciences industry, today announced that Titan Pharmaceuticals, Inc. has selected Tika’s BI/CRM platform to deliver real-time, actionable intelligence and interactive advanced analytics to its Sales and MSL teams. Titan is focused on the U.S. commercial relaunch of Probuphine® (buprenorphine) implant, its unique six-month maintenance treatment for Opioid Use Disorder (OUD).
With its unique ability to aggregate information and combine the functionality of disparate sales and marketing tools, TikaMobile will operate as Titan’s one-stop solution for its CRM and analytic needs. This will allow Titan to continue to strengthen its product launch process and leverage its Sales team to increase productivity and better drive revenue. Titan’s MSL team will also have insights to better focus on KOLS to build stronger relationships and manage ongoing training initiatives with prescribers.
“We are pleased to be partnering with Titan as they work to change the medical landscape with their unique long-term maintenance treatment for opioid use disorder,” commented Manish Sharma, Chief Executive Officer and founder of TikaMobile. “Our advanced CRM and audience targeting capabilities will provide Titan with the intelligence and insights that their field reps need to increase their productivity, boost revenue generation and enhance the efficiency of their overall business practices.”
“Our field personnel appreciate the user-friendliness of the Tika system and the ability to view complex data in a simple and meaningful way,” said Titan’s EVP and Chief Commercial Officer, Dane Hallberg. “We believe that Tika will provide our teams with a highly efficient way to identify opportunities, support our customers, and more-effectively manage our business in this competitive environment.”
About TikaMobile, Inc.
TikaMobile, Inc. is the premier leader in cloud-based business intelligence and CRM sales enablement software for the global life sciences industry. By combining many disparate sales and marketing tools into a single easy-to-use application, while applying prescriptive, actionable analytics across the commercial organization, Tika is transforming and optimizing sales organizations for pharmaceutical and medical device companies. Tika is committed to innovation, product excellence, and customer success and works with organizations of all sizes. Headquartered in New York City, Tika has offices in the United States, Europe and India. For more information, visit www.tikamobile.com.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine® (buprenorphine) implant, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Robert Thomas | TikaMobile, Inc.
(646) 650-5545 | rthomas@tikamobile.com
Never heard back from the NASDAQ noncompliance guy at 301 978-8092----But---Titan is off the noncompliance list now.
I called this number at NASDAQ and got the desk of Ben Haskell----Got his voice recording & "I'm sorry I can't take your call right now, please leave a message" 301 978- 8092
EXCHANGE TRADED PRODUCTS
Listing Qualifications - Initial and Continued Listings ETP Listing Applications (including switched from other exchanges)
ETP initial and continued listing standards and processes Ben Haskell
Director, ETP Regulation
+1 301 978 8092
benjamin.haskell@nasdaq.com
It's like being on a see-saw---We're all on one end, and there's a ton of "road apples" (horse$hit) on the other end----and we're waiting & watching for the apples to hatch out into dollars.
--------------------------------------------------------------------------------------------------------------------------
PS: For those of you who aren't countrified people: From your Funke & Wagnall:
Noun. road apple (plural road apples) (idiomatic, dated, often pluralized) Horse manure, especially when deposited on a road.
The float is # of shares held by "traders"---OS is total of what can be bought---depends on how the mm's would increase the "ask" as shares are bought up---But---mm's make "deals" for large buys. Any related Pharma that would want probuphine implant proneura in their bag of tricks, will be more interested now. (maybe)----The term "float" is also used as the OS number sometimes, and the OS can refer to everything including restricted & preferred shares, & etc shares, as related to the total AS (authorized shares)
Anything positive at this time , increases the % of probability that TTNP will be bought out or "taken over". Hostile takeover of buying up 51% of OS is "real" now.
You DO NOT understand----A lot of us got in around $6---rode it down to 6 to1 R/S---When it was 6 dollars, it was projected to go to 12---maybe 20.--go figger !!!!!!----Approx 1/30 of original value.
I've had some "losers" thru the years, but this one "takes the cake"----for all the known reasons we've been posting about for the last few years----Sure would be nice if a related Pharma decided to need this in their repertoire of drugs. "Truth"----You understand this problee better than anyone on this board.
EMERGENCY ALERT !!!!!---- Pump Crew-----TTNP dropping like a hot potato---Youse guys is slackin' off dis mornin'.----Snuff your doobies & get busy pumping----but---Do it professionally so it sounds good to the rest of the world----This is an International message board & the whole world is listening. Hup 2 3 4, Hup 2 3 4.----NOW !!!!!!!!! We're counting on YOU !!!!!!! Put your best lipstick on this pig !!!!!!
WELCOME "Pump Crew"---to good news------Put some lipstick on this pig & pump it to da "MOON" !!!!!!!
All 3 of youse has got it confuzed---Dis iz a sinister plot to give themselves 1/2 mil$ salary per year & options up the geegeech!!!!!!!-----What else goes on behind closed doors ????? LOLOL The "Shadow" knows.
"Who knows what evil lurks in the hearts of men? The Shadow knows!"
http://www.oldradioworld.com/shows/The_Shadow.php
This SUX !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Titan Pharmaceuticals Announces Reverse Stock Split
PR Newswire PR Newswire•January 24, 2019
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a commercial stage company developing proprietary therapeutics using its ProNeura™ long-term continuous drug delivery technology, announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-6 reverse stock split of the company's issued and outstanding shares of common stock, warrants and options, which was approved by the company's stockholders at a special meeting held on January 23, 2019. The reverse stock split will become effective at 5:00 pm Eastern Time on January 24, 2019, and the company's shares of common stock will begin trading on a split-adjusted basis on the NASDAQ Capital Market ("NASDAQ") at the commencement of trading on January 25, 2019 under the company's existing symbol "TTNP." The company's common stock has been assigned a new CUSIP number of 888314507 in connection with the reverse stock split.
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
More
The reverse stock split is intended to increase the per share trading price of Titan's shares of common stock to satisfy the $1.00 minimum bid price requirement for continued listing on NASDAQ, and to provide the company with available shares for future business and financing transactions. At the effective time of the stock split, every 6 shares of Titan's outstanding common stock will be converted to 1 share of issued and outstanding common stock. The reverse stock split will not affect any stockholder's ownership percentage of Titan's common stock, except to the extent that the reverse stock split would result in any stockholder owning a fractional share. Fractional shares of common stock will be rounded up to the nearest whole share. Immediately after the reverse stock split becomes effective, Titan will have approximately 12,995,000 shares of common stock outstanding.
All of the company's outstanding options and warrants will also be adjusted to reflect the reverse split by dividing the number of shares of common stock into which the options and warrants are exercisable by 6 and multiplying the exercise price thereof by 6 all in accordance with the terms of the plans, agreements or arrangements governing such securities.
INFORMATION FOR STOCKHOLDERS
Titan's transfer agent, Continental Stock Transfer & Trust Company, which is also acting as the exchange agent for the reverse split, will provide instructions to stockholders regarding the process for exchanging share certificates. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole post-split share and no stockholders will receive cash in lieu of fractional shares.
Nice & peaceful & quiet in here without the limited intellectual (Can't use the "R" word) Pump & Dump crew with their atrocious syntax & spelling & upside down & backward thought processes. Shareholder's meeting today with R/S vote may bring the P&D crew back depending on whether there is also good news instead of bad (unlikely). Either way, We'll problee have to listen to all their jive-a$$ $hit rapping again. Wouldn't it be nice if Sunil & Marc now have a new positive $$$$$$ program in the works ???.
Having a secondary offering to float more shares on the OS total, and then taking 4 or 5 times that number "back" with a R/S is SOOOOOOO----- "UPSIDE DOWN" !!!!!!!!!!!! ----& backwards -----A $$$ mill for Sunil & Marc (& cohorts) -----I feel like such a "jerk" & "shumdit" for being under their thumb. Sumbodee----Puleeeeez do something to cure my mizzeries. Please hear my plea---related Pharma companies.
I got a "Happy Holiday" post card from HUB usa IFBC, sent Jan 3 from 18-13 B 42nd St, suite #101, Astoria, NY---- Picture of "HUB" energy drink on it & website address----- ifbchubusa.com ---- and joint venture & company information on the backside----nice surprise !!!!!!
Check this out-------http://ifbchubusa.com/
Looks like a "fluke"----sooooo sad
Up 3 cents today on higher volume---unusual for a Friday---Brainteaser?----Somebody knows something ????-----Just a fluke ?----or some insider info is leaking out ?????--- "What's up"? If insider info is leaking out---Monday will open higher after it gets "passed around". If you have 24/7 broker to call---like Schwab----Call on Sunday & see if they will tell you how the buys & sells are stacking up for opening bell Monday.
"Takeover"--yes-- --"Merger"--no---You may be right, but I think you're wrong---Sunil & Marc don't seem to be "assimilators" with other execs. Smells like you got caught up in the rapture of the moment with your "P&D" crew & became "complacent" & didn't "dump" in time.
The legal fees from SEC savvy attorneys,---accounting fees from high dollar SEC approved & bonded accountants, and related & associated fees can cost upwards of 1/4 million dollars---to gain NASDAQ status
https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/
Hi Melody----Always nice to hear your wisdom----I don't think they ever wanted to "sell" & let their paychecks go- --(I believe that was your sentiment too---correct me if I'm wrong)---It would have to be a hostile takeover---or some where on that level. If they lose NASDAQ status, it's verrrry Xpensive to get it back---(problee at least $250,000)---so an R/S is in order----The shareholders can't outvote Sunil & Marc, as they have "preferred" shares that have a gazillion voting rights each (I believe). The "vote" was just a legal formality to satisfy SEC reqs.
Sounds like you bought in before you were aware of the R/S, and now U R A "Nervous Norvus", LOL
Well,-----That's life in the fast lane.--LOL
Titan is entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. The agreement supersedes the previously executed term sheet that contemplated a license arrangement with respect to the intellectual property Titan has sold to Molteni.
This is from:
https://ir.titanpharm.com/press-releases/detail/189/titan-executes-agreement-for-acquisition-by-molteni-of
-------------------------------------------------------------------------------------------------------------------------
PS: If Titan makes you unhappy & depressed----Do the "Buyout & Takeover Boogie".
Titan stays on NASDAQ----We get screwed (as always)---We need to know what actually goes thru the minds of TTNP Execs---(seems obvious by now)---Maybe a miracle accession by the competition.
I believe we've all come to that conclusion "Somewhere along the way". Need a miracle worker now.
"'Verry Merry Christmas" TTNP Xmas people !!!! -----"Hairy Grinchmas" to Sunil & Marc-----May we have a TTNP takeover verrry soon !!!!!!!!!